The collaboration will support development of Ascidian's RNA exon editor therapy, ACDN-01, for treating the rare genetic eye disease.

New research provides a mechanistic map of how genetic mutations disrupt RNA splicing in acute myeloid leukemia.

Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...

Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...

SpliceBio, a clinical-stage genetic medicines company pioneering protein splicing to address diseases caused by mutations in ...

A new research paper featured as the cover of Volume 17, Issue 12 of Aging-US was published on December 22, 2025, titled "A combination of differential expression and network connectivity analyses ...

Alloy Therapeutics today announced the appointment of Christian Cobaugh, Ph.D., as Chief Executive Officer of Alloy Genetic ...

Researchers analyzed gene expression and network connectivity across eight human tissues and found shared aging-related ...

Our results demonstrate that differential connectivity analysis reveals significant transcriptional alterations that are not ...

A new research paper featured as the cover of Volume 17, Issue 12 of Aging-US was published on December 22, 2025, titled “A ...

Mechano-Growth Factor (MGF), often referred to as the IGF-1 Ec isoform (or IGF-1 Eb), is a splice variant of the insulin-like ...